

A Study on a Full-Cycle Compliance Governance Framework for Biotechnology Companies —A Case Study of Huaxi Biotech Co., Ltd.

Leqian Ni¹, Chenyang Li¹

¹ E-Commerce Program, Jinan University, Shenzhen 518053, China

Corresponding Author: nileqian@stu2024.jnu.edu.

ABSTRACT

Based on current laws and regulations, the annual reports of Huaxi Biotech Co., Ltd. from 2020 to 2025, litigation cases and relevant practical materials available to the public, the paper analyzes the legal problems encountered by Huaxi Biotech Co., Ltd. in corporate governance, contract performance, intellectual property rights and risk management. The study suggests that biotech companies are confronted with interconnected compliance risks concerning joint R&D ownership, international contract performance, non-compete obligations, trade secret protection, protection of trademark rights, and risk allocation. The paper calls for a holistic compliance governance system based on the principles of contractual freedom, fair dealing and good faith, which entails “prevent rights clarification, in-process evidence preservation and post-event fallback measures”. Since the results are based on one case study and publically available data, the proposed framework is a normative proposition and its operational effectiveness needs to be empirically tested.

KEYWORDS: *Biotechnology Firms; Regulatory Adherence and Oversight; Agreement Administration; Intellectual Assets; Risk Mitigation*

Date of Submission: 09-09-2026

Date of acceptance: 20-09-2026

I. INTRODUCTION

The biopharmaceutical industry is a high-technology, capital-intensive industry with extended research and development cycles and stringent regulatory oversight. The globalization of corporate activity and the development of synthetic biology technologies mean that corporate behavior must comply with civil and commercial statutes and also faces compliance challenges in product quality, market entry, international trade, and intellectual property rights. For companies that rely on imported reagents, outside research alliances and multi-channel marketing, customs authorizations, advertising constraints, contract execution and validation of technology rights have become interlocked.

Contemporary regulatory approaches have developed from the control of single phases to constraints along the entire continuum. The regulations for reducing commercial bribery risks in the pharmaceutical industry have transformed compliance from reactive to proactive prevention. The Anti-Unfair Competition Law enhanced the accountability of organizations and individuals, and Biosafety Law laid out the rules on declaration, quarantine and market entry for the import and export of microorganisms and biological products. Meanwhile, extraterritorial export rules and interagency enforcement have increased the uncertainty about corporations' foreign sales, technical alliances, and financial operations. Biotech enterprises must consider regulatory oversight, supply chain integrity, transactional agreements and intellectual property protection within an integrated governance framework.

Huaxi Biologics is involved in the full spectrum of synthetic biotechnology research and development, raw material production, health care industry and consumer sector. The practical legal challenges are mainly related to the unclear ownership of the joint R&D results, the compliance with the marketing requirements when the B2B2C transition happens, the performance unpredictabilities due to the multinational supply chain assessments and the governance obligations in the transnational business. The study investigates how firms can develop a viable compliance framework that matches risk reduction with operational efficiency, with corporate governance as the foundation and contract and intellectual property systems as key instruments.

II. MATERIAL AND METHODS

The methodology used in this paper is a literature review and single-case study. The study resources consist of up-to-date statutes and regulations such as the *Company Law*, the *Anti-Unfair Competition Law*, and the *Biosafety Law*. It also includes Huaxi Biologics' annual reports from 2020 to 2025, IPO documentation, publicly available litigation cases, and compliance materials distributed by legal firms. The review covers four areas: corporate governance, contract execution, intellectual property and risk management. Such internal business contracts, information on policy execution or interview resources were not received by this document.

III. CASE STUDY: BLOOMAGE BIOTECH REGULATORY OVERSIGHT

Huaxi Biotech Co., Ltd. is a biotech company specialized in synthetic biology, founded in 2000. The enterprise has evolved from bioactive raw materials (including hyaluronic acid) to medical applications, dermatology and nutritional science. It follows a business model combining in-house production, external manufacture, distribution and direct online sales. The development of the business network has expanded the range of contractual situations such as procurement, R&D partnerships, contract manufacturing, distribution, marketing and post-sales services, while at the same time increasing risks in relation to intellectual property protection, product liability and the execution of international contracts.

During the production phase, the company manufactures mainly its biofermentation-derived raw materials and medical end-use products and most of its functional skincare products in-house, although other skincare products and food products are produced through contract manufacturing. In-house manufacturing entails a continuous process of regulatory compliance for pharmaceuticals, medical devices, cosmetics, and quality management; while outsourced production involves the transfer of formulations, raw materials, packaging, quality assessment and liability through contractual arrangements. The sales section covers sales of raw materials to manufacturers, sales of finished products to healthcare facilities, sales of finished products to consumers through the Internet, and platform cooperation. This multi-entity, multi-channel business model means the compliance difficulties of the organization are not contained to a single contract but span the entire transaction continuum from research and development, procurement, manufacturing, marketing and post-sales service.

IV. RESULTS

A. Governance of Corporations and Organizational Norms

Huaxi Biologics has evolved from a Sino-foreign joint venture and limited liability company to a publicly traded joint-stock company on the STAR Market. The governance has shifted from the independence of shareholders to the governance regulation of a public firm. Once listed, the firm can access capital markets to improve research and development and production capacity, and to assume obligations such as ongoing disclosure, internal governance and voting on critical matters. The Articles of Incorporation are the permanent governance structures and the Founders' Agreement is the tools to validate the rights and responsibilities during the reorganization time. The main structure of checks and balances is provided by the General Shareholders' Meeting, the Board of Directors, the Board of Supervisors and executive management. An important institutional mechanism to reduce risks related to centralized power, technology transfer, and corporate activities is the centralized monitoring of major matters at subsidiaries and the signing of employment, confidentiality, and non-compete agreements with key personnel.

The "Promoters' Agreement" recognized the promoters, the transformation of net assets into shares and the establishment duties as a private contract, and the "Articles of Incorporation" laid down the governance rules as permanent rules applicable to the company, shareholders, directors, supervisors and senior management. Successive application of both contracts marks transition of the company from internal consensual constraints to regulatory supervision of a public business. For listed companies with concentrated ownership, independent directors, supervisory board, internal audit and subsidiary management systems are used to explicitly oversee and supervise the operational powers of the controlling shareholders and management.

B. Contract Execution Hazards and Safeguards

The Huaxi Biologics is engaged in the manufacturing of raw materials, manufacturing of finished goods and market sales; and including complex transactional conditions of procurement, outsourced research and development, contract manufacturing, labor oversight and product distribution. The conflicts related to them mostly include payment issues, product distribution, quality control of outsourced production and responsibility for breach of contract, according to the case files available to the public. Transnational partnerships create difficulties in the areas of governing law, arbitration institutions, project termination, and liquidation of assets; when research and development and employment contracts have not adequately defined the division of

investments, ownership of interim results, technical confidentiality and non-compete provisions, they may increase the risk of commercialization and mobility of talent.

In manufacturing and distribution partnerships involving outsourcing, the lack of formal agreements on quality control standards, delivery dates, procedures for accepting products, and post-sale commitments could result in disputes about product faults, payment terms, and liability for breach of contract. Interregional and transnational partnerships may prolong the time to get remedies due to differing choices of governing law, arbitration clauses, judicial standards, and enforcement procedures. What is unusual about R&D partnerships is the fact that technological inputs are often delivered in phases and the format of outputs and the level of contributions are continually in flux. Resolving issues of ownership to vague language like “joint ownership” or “to be negotiated separately” may make it more difficult to facilitate future revenue sharing for commercialization, patent filings and technology licenses.

The focus of contract management should be “pre-establishing rights, documenting evidence throughout the process and safeguarding rights thereafter.” Research and development agreements should define inputs, ownership and profit distribution through a comprehensive list of deliverables; procurement and outsourcing contracts should specify quality standards, acceptance criteria and liability for compensation, keeping consistent records of logistics, inspections and reconciliations; distribution contracts must clearly set out regulations for settlement, dispute resolution and contract breaches; and cross-border contracts should pre-emptively stipulate governing law, dispute resolution, exit strategies and liquidation procedures. The emphasis of holistic contract management is not on adding more terms but on ensuring that rights and duties, documentation and recourse procedures are coherently integrated.

The inspection of cross-border transactions should be carried out before the signing of the contract. Besides cost, one should consider product market accessibility, export regulations, sanctions registries, intellectual property agreements, tax and fee sharing, currency exchange rates and payment channels, and select a suitable dispute resolution mechanism depending upon the geographical context of the transaction and asset allocation. The termination clauses of the project should include the outstanding items, technical documentation, termination of the license, claims and liabilities and cooperation in liquidation. There should be a contract drafted with business exit alternatives. This is to avoid extended stalemates and continuous confrontations when the parties cannot reach a common goal.

C. Safeguarding Intellectual Property and Trade Secrets

While Huaxi Biotech had historically concentrated on biological fermentation and cross-linking technology, it has expanded into a broad range of consumer brands. According to publicly available court cases, the risks of intellectual property are mostly limited to trademark infringement, ownership disputes and unfair competition. The growth of brands has increased the costs of defending against counterfeiting and deceptive marketing. In industry-academia collaborations, a lack of clear definition of technical contributions, interim results, and commercialization profit sharing can easily lead to ownership disputes. The loss of key personnel may also result in the unauthorized disclosure of proprietary information such as strain data, process specifications, and formulations.

Development of intellectual property governance should be coupled with contract management. Complete all necessary trademark and copyright registrations before product launch; clearly define the scope of authorization and liability for infringement in distribution and co-branding agreements; define a schedule of deliverables in collaborative R&D contracts, including ownership of outcomes, improvements to outcomes, and revenue distribution; govern core technologies through tiered and decentralized frameworks, including employee responsibilities via confidentiality and non-compete agreements; in cases of infringement, quickly preserve electronic evidence and seek a preservation order, in accordance with legal standards. It is a technique that transforms trademarks and technologies from simple objects of rights protection into identifiable and manageable economic goods.

According to a governance rule, the protection of intellectual property should include four stages of production, rights affirmation, use and reparation. The creation phase establishes the basis of accomplishments through R&D documentation and individual roles verification, the rights establishment phase determines the protection mechanisms such as patents, copyrights or trade secrets depending on the technical features, the utilization phase governs the authorization parameters, quality standards and profit sharing through licensing agreements, and the remedy phase alleviates damages through evidence preservation, administrative complaints, legal proceedings and injunctive measures. The four phases are interconnected, which avoids the problem of focusing solely on the quantity of rights rather than their quality and their efficacy.

D. Risk Distribution and Protective Measures

Contracts and intellectual property arrangements can not eliminate business risks. Companies should also introduce risk-sharing instruments tailored to specific business situations. Companies could explore export

credit insurance for international sales, performance bond insurance for domestic agency agreements or outsourcing arrangements, liability insurance for the distribution of medical devices to mitigate product liability and recall risks, and cybersecurity liability insurance for the management of R&D data and trade secrets in digital form. Publicly listed companies should also consider directors, supervisors and senior management liability insurance in light of the risks of their leadership roles. Insurance covers only those damages that are within its defined scope and cannot replace contract review, corporate governance or legal duties.

Insurance plans have to be based on the identification of risk and assessment of potential loss. Companies will need to distinguish between high-frequency/low-loss and low-frequency/high-loss risks and prioritize coverage based on an assessment of contractual liability limits, supply chain concentration, product recall scope, data asset value and cross-border litigation costs. Companies should be aware of differences between insurance contracts and business contracts in terms of liability coverage before buying insurance, such as where a business contract would include more liability to pay compensation but the insurance policy excludes the relevant cases. Insurance can generally be an effective auxiliary to internal controls only if coverage limitations, deductibles and claims form requirements are consistently evaluated.

E. Marketing and Retail Operations Adherence

Huaxi Biotech has expanded its business from raw materials to medical retail, functional skincare and nutritional products, reaching consumers through e-commerce channels, proprietary platforms, distributors and physical shops. The B2B2C model has broadened the market reach and eased product marketing, platform partnerships, distributor management, and after-sale responsibilities. The extent to which the company is exposed to administrative, civil or reputational risks depends on the boundary between medical education and commercial promotion, permissible promotional claims for different categories of products, and the consistency of platform pages, live-streaming content and advertisements of distributors.

For retail businesses, regulatory compliance should be built into content creation, channel distribution and post-sale processes. Organizations need to substantiate the claims made in their marketing about the characteristics of their products so as not to falsely promote ordinary cosmetics or food products as having therapeutic benefits. They must conduct assessments before releasing platform stores, livestream scripts, distributor resources and co-branded materials and control the versions of these items. Distribution contracts must clearly set the limits on promotion, the source of the content, how grievances will be handled and who will be responsible for any breaches. Organizations must quickly gather and share consumer feedback, product quality measures and details of any adverse events with the production, legal and after-sales departments. Standardized content guidelines and a clear accountability structure can also help firms mitigate compliance risks that arise from misinformation, illegal control, or slow responses in multi-channel operations.

V. DISCUSSION AND CONCLUSION

Empirical studies suggest that the main competitive advantage of first movers in biotech is not just in technological research and development and product development, but also in their ability to manage risks in a methodical and legal manner. Corporate governance lays out the division of internal responsibilities. Contract management establishes the rights, duties, and documents that accompany transactions. Intellectual property regimes protect technology and brand assets. And instruments such as insurance help to mitigate remaining risks. For enterprises to move from a reactive posture in dealing with conflicts to a proactive stance in preventing disagreements in the course of commercial activities, these four components must be a closed-loop system.

The framework of “pre-transaction rights clarification, in-transaction evidence preservation, and post-transaction fallback” proposed in this paper improves transaction structures through party autonomy, balances the rights and obligations of collaboration through fair practices, and regulates market activities and internal administration through the principle of good faith. Limitations of applicability of this study Existing research resources: This paper is a single-case study based on public disclosures and illustrative cases without access to internal contract documents, operational data or interview materials, so it can not be concluded that Huaxi Biologics has fully adopted this framework. The real effectiveness of concerned measures still has to be verified through their application in companies and the subsequent research.

REFERENCES

- [1]. O. Hamlyn, Synthesize this: integrating innovation governance and EU regulation of synthetic biology, *Journal of Law and Society*, Vol. 49, No. 3 (2022), pp. 577–602. <https://doi.org/10.1111/jols.12375>
- [2]. D. Stemerding, W. Betten, V. Rerimassie, Z. Robaey and F. Kupper, Future making and responsible governance of innovation in synthetic biology, *Futures*, Vol. 109 (2019), pp. 213–226. <https://doi.org/10.1016/j.futures.2018.11.005>
- [3]. I. Brown, A. Steen and J. Foreman, Risk management in corporate governance: A review and proposal, *Corporate Governance: An International Review*, Vol. 17, No. 5 (2009), pp. 546–558. <https://doi.org/10.1111/j.1467-8683.2009.00763.x>
- [4]. D. T. Robinson and T. E. Stuart, Financial contracting in biotech strategic alliances, *The Journal of Law and Economics*, Vol. 50, No. 3 (2007), pp. 559–596. <https://doi.org/10.1086/519811>

- [5]. A. Phene and S. Tallman, Complexity, context and governance in biotechnology alliances, *Journal of International Business Studies*, Vol. 43, No. 1 (2012), pp. 61–83. <https://doi.org/10.1057/jibs.2011.53>
- [6]. J. Kim, Formal and informal governance in biotechnology alliances: Board oversight, contractual control, and repeated deals, *Industrial and Corporate Change*, Vol. 23, No. 4 (2014), pp. 903–929. <https://doi.org/10.1093/icc/dtt045>